Clinical trial Recruiting at 1 site Observational Ages 18 and up

SOFA-2 scoring for ICU patients in Türkiye

Official title: Real-Time Validation and Feasibility of the SOFA-2 Score in Adult Intensive Care Units in Türkiye (TR-SOFA2): A Multicenter Prospective Observational Study

Run by Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital · NCT07338240 · Data updated 2026-11-12

This project will test whether the updated SOFA-2 organ failure score predicts survival for adults admitted to intensive care units in Türkiye.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment5200 (estimated)
SponsorIzmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital
Academic / other
Locations1 site (Izmir, İzmir)
StatusRecruiting
StartedJanuary 19, 2026
Main results expectedJune 2026
Study endsJuly 2026
Registry record updatedJanuary 21, 2026
Trial IDNCT07338240 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older admitted to a participating intensive care unit in Türkiye who remain in the ICU for more than 24 hours (excluding pregnant patients and organ donors) are the intended candidates.

Probably not a fit

Patients under 18, pregnant patients, organ donors, those discharged or transferred within 24 hours, or those with unknown ICU outcomes are unlikely to benefit from this study's findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter prospective observational project will follow adult patients admitted to participating ICUs in Türkiye and record routinely collected clinical and laboratory data. SOFA and SOFA-2 scores will be calculated from data obtained during the first 24 hours of ICU admission and again at 72 hours for longer stays. No extra tests or treatments will be performed beyond standard clinical care. Patients will be followed until ICU discharge or death to measure the relationship between SOFA-2 scores and ICU mortality. The study will also compare SOFA-2 performance against the original SOFA score and account for differences across centers.

Why it matters

Potential benefit: If successful, SOFA-2 could give clinicians a more accurate way to predict ICU mortality and help guide triage and monitoring decisions.

How similar studies have gone: The original SOFA score is widely validated for ICU mortality prediction, while SOFA-2 is a newer update with limited external validation to date.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults aged 18 years or older
* Admission to a participating intensive care unit in Türkiye
* Intensive care unit stay longer than 24 hours

Exclusion Criteria:

* Patients younger than 18 years
* Pregnant patients
* Organ donors
* Patients with unknown intensive care unit discharge outcomes

Where it's running

  • University of Health Sciences Turkey, İzmir School of Medicine, Dr. Suat Seren Chest Disease and Thoracic Surgery Training and Research Hospital, Intensive Care Unit
    Izmir, İzmir, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.